Welcome to our dedicated page for Privia Health Group news (Ticker: PRVA), a resource for investors and traders seeking the latest updates and insights on Privia Health Group stock.
Privia Health Group operates as a U.S. physician enablement company focused on primary-care centric medical groups, risk-bearing entities and the Privia Platform of technology and service solutions. The company works with medical groups, health plans and health systems to build provider networks and support value-based care.
Company updates commonly cover quarterly and annual operating results, guidance, practice collections, care margin, platform contribution, adjusted EBITDA and provider growth. Recurring developments also include performance in value-based risk arrangements, expansion into new or existing states, material agreements, capital-structure disclosures and governance matters.
Privia Health Group, Inc. (Nasdaq: PRVA) has appointed Dr. Jaewon Ryu to its Board of Directors, expanding the board to nine members. This strategic move aims to leverage Dr. Ryu’s extensive experience in value-based reimbursement and patient care management to support the company's growth across the U.S. Dr. Ryu is currently the President and CEO of Geisinger and has held various leadership roles in healthcare. The board believes his expertise will significantly benefit Privia Health's initiatives in enhancing patient experiences and delivering high-value care.
Privia Health Group, Inc. (Nasdaq: PRVA) will join the Russell 2000 Index after the U.S. market opens on June 28, 2021. This addition follows the company's recent IPO and is expected to enhance awareness, increase stock liquidity, and broaden the shareholder base. The Russell 2000 Index tracks the performance of the 2,000 smallest stocks in the Russell 3000 Index, which comprises the largest U.S. companies. The reconstitution of Russell indexes is significant for investment strategies, with over $10.6 trillion in assets benchmarked to these indexes.
Privia Health Group, Inc. (Nasdaq: PRVA) announces its participation in upcoming investor conferences. On June 3rd at 10:20 am ET, they will present at the William Blair Growth Stock Conference, followed by the Goldman Sachs Global Healthcare Conference on June 10th at 1:20 pm ET. The events will be available via live webcast and on-demand replay, along with accompanying slide presentations. Privia Health focuses on enhancing physician practices and patient experiences through technology and collaboration with health systems and plans.
Privia Health Group, Inc. (Nasdaq: PRVA) reported a Q1 2021 revenue of $213.6 million, a modest increase of 0.3% from the previous year. The company achieved operating income of $7.9 million, up 21.7%, and net income of $5.4 million with an EPS of $0.06, unchanged year-over-year. Practice collections rose 5.1% to $344.1 million, while value-based care attributed lives declined 4.1% to approximately 721,000. The company has provided guidance for FY 2021 with expected revenue growth of 5.3% to 7.7%.
Privia Health Group (Nasdaq: PRVA) announced plans to release its financial results for Q1 2021 on May 27, 2021, after market close. The release will occur at 4:00 pm ET and will be accessible on the Company’s Investor Relations website. Following this, management will host a conference call at 5:00 pm ET to discuss the results and future outlook. Participants can join via webcast or by phone at 855-940-5315, using participant code 1076290.
Privia Health Group, Inc. (Nasdaq: PRVA) successfully closed its initial public offering (IPO) of 22,425,000 shares at $23.00 each, raising approximately $131.7 million before expenses. The offering consisted of 5,725,000 shares from Privia Health and 16,700,000 shares from a majority stockholder, who will not provide proceeds to Privia. The IPO included the full exercise of the underwriters' option for 2,925,000 additional shares. Trading commenced on April 29, 2021, under the symbol 'PRVA'.
Privia Health Group announced the pricing of its IPO, offering 19.5 million shares at $23.00 each, raising approximately $64.4 million in gross proceeds. The offering includes 2.8 million shares from Privia Health and 16.7 million from its majority stockholder. Shares will begin trading on Nasdaq under the ticker symbol 'PRVA' on April 29, 2021. Proceeds will fund general corporate purposes, including R&D and potential acquisitions, although no agreements are in place for such investments. The offering is set to close on May 3, 2021.